Drug facts

Is compounded tirzepatide safe?

By David Chen·Editor·Reviewed September 2026

Two questions, not one

The two are easy to blur. The first is about the drug and the answer comes with the prescription. The second is about the pharmacy, the shipping and the syringe, and that is where a compounded vial differs.

What the drug carries¹

• A boxed warning, FDA’s strongest: tirzepatide causes thyroid C-cell tumors in rats, and whether it does in people is unknown. It is not to be used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2 — the warning, verbatim.
• Common stomach side effects. In the obesity trials nausea affected 25–29% of participants against 8% on placebo, and diarrhea 19–23% against 8% — every reaction with its placebo rate.
• Serious warnings, including acute pancreatitis, kidney injury from dehydration, and low blood sugar alongside insulin or a sulfonylurea — interactions, and pregnancy and contraception.

All of that attaches to the molecule, so it applies to a compounded vial exactly as it does to Zepbound. What the label cannot tell you is anything about the vial itself.

What compounding adds²

FDA’s own summary of the risk, from its compounding questions and answers:

Unnecessary use of compounded drugs may expose patients to potentially serious health risks. For example, poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient. This can lead to serious patient injury and death.

For compounded GLP-1 drugs, tirzepatide among them, FDA points to three places it goes wrong.³

• The dose. FDA has received adverse-event reports that may be related to patients prescribed compounded semaglutide or tirzepatide “in doses beyond what is in the FDA-approved drug label” — a bigger single dose, more frequent doses, or faster increases. Some patients sought medical attention for nausea, vomiting, diarrhea, abdominal pain and constipation. The approved schedule is on the dosage chart, and measuring a dose from a vial is on units and milligrams.
• The vial. FDA recommends discarding a multi-dose vial 28 days after first use because contamination risk rises after that, and not using any GLP-1 that arrives warm — storage and beyond-use dating.
• The ingredient. FDA keeps an import alert to stop GLP-1 active ingredients with potential quality concerns from entering the US supply chain — which is why the pharmacy behind a seller, and where it sources from, is worth asking about.

What FDA has counted³

As of 31 May 2026, FDA had received more than 730 reports of adverse events associated with compounded tirzepatide. A report is not proof that the drug caused the event, and a count of reports says nothing about how many people took the drug, so it is not a rate. What it does establish is that FDA is watching, and that much of what it describes is about dosing.

FDA also writes to companies. Of the 402 sellers in this index, 43 hold an FDA warning letter matched to their operating company — each published in full on the trust page and on the seller’s own page here. ⁴

The risks you can reduce

• Know the pharmacy. A seller should name the licensed pharmacy that makes your vial — four checks, ten minutes.
• Know the concentration, in milligrams per milliliter, and check the arithmetic before every new vial with the dose-in-units calculator.
• Follow the approved schedule — 2.5 mg for four weeks, then steps no closer than four weeks apart — unless your prescriber has a documented reason not to.
• Mind the cold chain and the calendar. Refuse a warm delivery, and discard an opened vial after 28 days.
• Tell your prescriber about every other medicine you take, and anything that goes wrong.

What compounded tirzepatide is, and who may legally make it now, is on what compounded tirzepatide is; whether it works is on does compounded tirzepatide work?